Both direct and indirect routes to engage STING are currently being explored for glioma therapy, including STING agonists, alternating electric field therapy (e.g., tumor-treating fields [TTFs]), radiation therapy, and oncolytic viruses. This evidence concerns the gene STING1 and central nervous system cancer.